Silk Therapeutics Closes $6M Series A2 Financing Round

silk-logoSilk Therapeutics, Inc., a Boston, MA-based provider of silk protein solutions for human health and wellness, closed a $6m Series A2 financing round.

The round was led by existing investor The Kraft Group of Foxboro, Massachusetts, with participation from new investors Lear Corporation and Highland Consumer Partners, as well as existing investors Sheri and Roy P. Disney; Richard Sackler, MD, with Summer Road, LLC; Erin Donohue and Ron Bresler, BML Group; and Altman Health Investments.

The company, which has now raised a total of $10.25m in Series A funding, will use the funds to expand its skincare product line as well as will begin to explore additional consumer markets.

Led by Dr. Greg Altman, CEO, and Dr. Rebecca Horan, Chief Operating Officer, Silk Therapeutics provides silk protein solutions for human health and wellness. The company has patented natural silk protein technology for use in consumer goods and medical applications and offers a skincare product line designed to renew, fortify and nurture the skin.




Join the discussion